Aeovian Pharmaceuticals Secures $55M Series B for Groundbreaking Epilepsy Treatment
December 28, 2025, 3:33 pm
Location: United States, California, Palo Alto
Employees: 1001-5000
Founded date: 1961
Aeovian Pharmaceuticals secured a significant $55 million Series B funding. This pivotal investment propels its lead candidate, AV078, into a Phase 2 study. AV078 is a first-in-class CNS-penetrant selective mTORC1 inhibitor. It targets severe refractory epilepsy associated with Tuberous Sclerosis Complex (TSC). TSC is a debilitating rare genetic disorder. Luma Group and CTI Life Sciences Fund co-led the oversubscribed round. Multiple prominent investors participated. New board appointments strengthen leadership. This funding represents a critical advance for patients. It addresses a profound unmet medical need in neurological treatment. The company aims for superior efficacy and tolerability for patients battling difficult-to-manage seizures.
Aeovian Pharmaceuticals made headlines. The Berkeley-based biopharmaceutical firm raised $55 million. This Series B financing round was oversubscribed. It marks a significant milestone for the clinical-stage company. The investment will accelerate development of AV078. AV078 is Aeovian’s lead candidate. It targets a severe neurological condition.
The funding round saw strong participation. New investors co-led the effort. Luma Group and CTI Life Sciences Fund spearheaded the financing. Other key participants included Foresite Capital and SymBiosis. The TSC Alliance Endowment Fund also invested. Wilson Sonsini contributed. Existing backers reaffirmed their commitment. Apollo Health Ventures, Hevolution, Sofinnova Investments, and venBio participated again. This broad investor support underscores confidence. It highlights AV078's potential.
Funds are earmarked for critical next steps. Aeovian plans to advance AV078. It will move into a Phase 2 proof-of-concept study. This study focuses on Tuberous Sclerosis Complex (TSC)-related refractory epilepsy. Accelerating development remains the core objective. The company prioritizes this underserved patient population.
AV078 is a unique therapeutic. It is described as a first-in-class molecule. It acts as a CNS-penetrant selective mTORC1 inhibitor. Its design aims for high selectivity. It specifically targets mTORC1. This selectivity is crucial. It differentiates AV078 from existing therapies. Current nonselective mTOR inhibitors can cause toxicities. These arise from mTORC2 inhibition. AV078 avoids this pitfall. It promises improved efficacy and tolerability.
Tuberous Sclerosis Complex (TSC) is a rare genetic disorder. Mutations in TSC1 or TSC2 genes drive it. These mutations lead to hyperactive mTORC1 signaling. This signaling pathway is critical. Its dysregulation causes widespread complications. These include benign tumors in vital organs. Neurological issues are common. Epilepsy stands as a major challenge.
Epilepsy in TSC patients is often severe. Many patients experience refractory seizures. These seizures persist despite available treatments. Current therapies frequently fall short. Managing these seizures is difficult. Patients suffer profoundly. A significant unmet medical need exists. AV078 aims to fill this void. It seeks to provide sustained seizure control.
AV078’s central nervous system penetration is key. Many neurological drugs struggle to cross the blood-brain barrier. AV078 overcomes this hurdle. It effectively modulates hyperactive signaling in the brain. This design supports its targeted approach. It offers hope for more effective brain-specific treatment.
Two new members joined Aeovian’s Board of Directors. Themasap Khan, Ph.D., now serves on the board. He is co-founder and partner at Luma Group. Youssef Bennani, Ph.D., also joined. He is managing partner at CTI Life Sciences. Their appointments bring diverse industry experience. They will guide Aeovian through its next growth phase.
Aeovian Pharmaceuticals maintains a broader pipeline. It focuses on metabolic quality control. This involves selective inhibition of mTORC1 or CD38. The company targets rare diseases. It also explores age-related conditions. This strategy reflects a commitment to precision medicine. It addresses complex biological pathways.
The successful Phase 1 study validated AV078's potential. This early success propelled the Series B funding. Investors recognized the promise. The drug could transform patient outcomes. For those with TSC-refractory epilepsy, this is critical. It offers a new path to relief.
The investment underscores confidence. It signals belief in Aeovian’s scientific platform. It also validates its leadership. The company’s targeted approach resonates. It targets the root cause of the disease. This is a crucial strategy in drug development.
This funding positions Aeovian for significant progress. The Phase 2 study will be pivotal. It aims to prove AV078's concept. Success would open doors to further development. It would bring a new option closer to patients. This is a major step forward for TSC community. It promises a brighter future for those battling refractory epilepsy. Aeovian Pharmaceuticals is advancing medical innovation.
Aeovian Pharmaceuticals made headlines. The Berkeley-based biopharmaceutical firm raised $55 million. This Series B financing round was oversubscribed. It marks a significant milestone for the clinical-stage company. The investment will accelerate development of AV078. AV078 is Aeovian’s lead candidate. It targets a severe neurological condition.
The funding round saw strong participation. New investors co-led the effort. Luma Group and CTI Life Sciences Fund spearheaded the financing. Other key participants included Foresite Capital and SymBiosis. The TSC Alliance Endowment Fund also invested. Wilson Sonsini contributed. Existing backers reaffirmed their commitment. Apollo Health Ventures, Hevolution, Sofinnova Investments, and venBio participated again. This broad investor support underscores confidence. It highlights AV078's potential.
Funds are earmarked for critical next steps. Aeovian plans to advance AV078. It will move into a Phase 2 proof-of-concept study. This study focuses on Tuberous Sclerosis Complex (TSC)-related refractory epilepsy. Accelerating development remains the core objective. The company prioritizes this underserved patient population.
AV078 is a unique therapeutic. It is described as a first-in-class molecule. It acts as a CNS-penetrant selective mTORC1 inhibitor. Its design aims for high selectivity. It specifically targets mTORC1. This selectivity is crucial. It differentiates AV078 from existing therapies. Current nonselective mTOR inhibitors can cause toxicities. These arise from mTORC2 inhibition. AV078 avoids this pitfall. It promises improved efficacy and tolerability.
Tuberous Sclerosis Complex (TSC) is a rare genetic disorder. Mutations in TSC1 or TSC2 genes drive it. These mutations lead to hyperactive mTORC1 signaling. This signaling pathway is critical. Its dysregulation causes widespread complications. These include benign tumors in vital organs. Neurological issues are common. Epilepsy stands as a major challenge.
Epilepsy in TSC patients is often severe. Many patients experience refractory seizures. These seizures persist despite available treatments. Current therapies frequently fall short. Managing these seizures is difficult. Patients suffer profoundly. A significant unmet medical need exists. AV078 aims to fill this void. It seeks to provide sustained seizure control.
AV078’s central nervous system penetration is key. Many neurological drugs struggle to cross the blood-brain barrier. AV078 overcomes this hurdle. It effectively modulates hyperactive signaling in the brain. This design supports its targeted approach. It offers hope for more effective brain-specific treatment.
Two new members joined Aeovian’s Board of Directors. Themasap Khan, Ph.D., now serves on the board. He is co-founder and partner at Luma Group. Youssef Bennani, Ph.D., also joined. He is managing partner at CTI Life Sciences. Their appointments bring diverse industry experience. They will guide Aeovian through its next growth phase.
Aeovian Pharmaceuticals maintains a broader pipeline. It focuses on metabolic quality control. This involves selective inhibition of mTORC1 or CD38. The company targets rare diseases. It also explores age-related conditions. This strategy reflects a commitment to precision medicine. It addresses complex biological pathways.
The successful Phase 1 study validated AV078's potential. This early success propelled the Series B funding. Investors recognized the promise. The drug could transform patient outcomes. For those with TSC-refractory epilepsy, this is critical. It offers a new path to relief.
The investment underscores confidence. It signals belief in Aeovian’s scientific platform. It also validates its leadership. The company’s targeted approach resonates. It targets the root cause of the disease. This is a crucial strategy in drug development.
This funding positions Aeovian for significant progress. The Phase 2 study will be pivotal. It aims to prove AV078's concept. Success would open doors to further development. It would bring a new option closer to patients. This is a major step forward for TSC community. It promises a brighter future for those battling refractory epilepsy. Aeovian Pharmaceuticals is advancing medical innovation.